Recent Updates
Recently added Catalysts
MYGN Positive Sentiment Score: 70/100

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Key Takeaway: Myriad Genetics, Inc. will hold its fourth-quarter earnings conference call on February 27, 2024, to discuss its financial results for 2023. The call will include a financial overview and an update on company performance, along with revenue and earnings guidance for 2024. Additionally, Myriad's management will participate in several investor conferences in March, reflecting ongoing investor engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Myriad Genetics is set to release its fourth-quarter and full-year financial results, indicating positive business activity.
  • The company is actively participating in investor conferences, suggesting continued interest and engagement in its initiatives.
  • Management will provide guidance for 2024, showing confidence in future performance.

Full Press Release Details

SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes.
During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2023. Revenue and earnings guidance for 2024 will also be shared.
A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. Following the conference call, an archived webcast of the call will be available at investor.myriad.com.
March Investor Conferences
Management will also be participating in the following investor conferences:
The 45th Annual Raymond James & Associates Institutional Investors Conference with a presentation from Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, on March 4, 2024, at 4:35pm EST.
The 44th Annual Cowen Health Care Conference with a fireside chat featuring Sam Raha, chief operating officer, and Ben Wheeler, chief financial officer – operations, on March 5, 2024, at 12:50pm EST.
A live and archived webcast of both presentations can be viewed in the investor relations section of Myriad’s website at  investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Frequently Asked Questions

When will Myriad Genetics release its Q4 earnings?

Myriad Genetics will release its Q4 earnings on February 27, 2024.

How can I access the earnings conference call?

The earnings call can be accessed via Myriad’s Investor Relations website.

Who will present at the Raymond James conference?

Paul J. Diaz and Scott Leffler will present at the Raymond James conference.

What is Myriad Genetics known for?

Myriad Genetics specializes in genetic testing and precision medicine.

Will there be a webcast of the investor conferences?

Yes, both presentations will have live and archived webcasts available.

Last updated: Feb 21, 2024